)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Protalix BioTherapeutics (PLX) investor relations material
Protalix BioTherapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Total revenues for the first nine months of 2025 reached $43.6 million, up 24% year-over-year, with Q3 revenues at $17.9 million, down 1% from Q3 2024.
Net loss for the nine months was $1.1 million, a significant improvement from a $3.6 million loss in the prior year; Q3 net income was $2.4 million.
Commercial success of enzyme replacement therapies continues, supporting R&D investments and pipeline advancement.
Regulatory re-examination requested for Elefabrio's every-4-weeks regimen in Europe, with a decision expected in Q1 2026; the approved every-2-weeks regimen remains unaffected.
Operating strategy focuses on commercial execution, pipeline advancement, and financial discipline.
Financial highlights
Nine-month product sales: $43.6 million (up 24%); Q3 product sales: $17.9 million (down 1%).
Cost of goods sold for nine months: $22.4 million (up 10%); Q3: $8.3 million (down 1%).
R&D expenses for nine months: $13.9 million (up 58%); Q3: $4.5 million (up 50%), mainly due to PRX-115 phase II preparations.
SG&A expenses for nine months: $8.2 million (down 11%); Q3: $2.9 million (up 12%).
Cash and equivalents at September 30, 2025: $29.4 million, sufficient for at least 12 months of operations.
Outlook and guidance
Confident in Elefabrio's long-term potential and ongoing global expansion efforts.
PRX-115 phase II trial to begin screening in late 2025, with top-line results expected in Q3 2027.
Cash runway guidance includes anticipated R&D expenses and royalty-based revenues.
No formal revenue or cash burn guidance provided, but management reiterates sufficient cash for over 12 months, including funding for PRX-115 phase II.
The company anticipates variability in period-to-period results due to the ordering patterns of commercial partners.
Will a new trial be needed for 4-week Elfabrio dosing?
What is the expected PRX-115 Phase II trial duration?
How to improve Elfabrio royalty revenue predictability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Protalix BioTherapeutics earnings date
Q4 202517 Mar, 2026
Next Protalix BioTherapeutics earnings date
Q4 202517 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Protalix BioTherapeutics Inc. is a biopharmaceutical company focusing on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. This technology enables the company to produce proteins with clinically improved profiles and to develop a pipeline of proprietary therapeutic proteins aimed at established pharmaceutical markets. Additionally, the company is developing other products, including treatments for cystic fibrosis and Fabry Disease, utilizing its platform to manufacture complex proteins, antibodies, and vaccines. The company is headquartered in Carmiel, Israel, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage